ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 627,57
-0,14%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immix Biopharma Inc (IMMX)

  7. Immix Biopharma Inc (IMMX) Actualités

IMMX

Immix Biopharma (IMMX)

Immix Biopharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IMMX
DateHeureSourceTitreSymboleSociété
21/05/202422h05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:IMMXImmix Biopharma Inc
20/05/202423h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMMXImmix Biopharma Inc
20/05/202423h27Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:IMMXImmix Biopharma Inc
20/05/202423h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMMXImmix Biopharma Inc
09/05/202422h27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMMXImmix Biopharma Inc
07/02/202423h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMMXImmix Biopharma Inc
28/11/202316h48InvestorsHub NewsWireImmix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient DosingNASDAQ:IMMXImmix Biopharma Inc
10/11/202301h57Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IMMXImmix Biopharma Inc
29/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMMXImmix Biopharma Inc
25/09/202322h15Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IMMXImmix Biopharma Inc
30/08/202322h15Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:IMMXImmix Biopharma Inc
23/08/202322h26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMMXImmix Biopharma Inc
25/07/202314h42GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual MeetingNASDAQ:IMMXImmix Biopharma Inc
17/07/202315h37GlobeNewswire Inc.Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical TrialNASDAQ:IMMXImmix Biopharma Inc
10/07/202315h47GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing SiteNASDAQ:IMMXImmix Biopharma Inc
26/06/202315h49GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical TrialNASDAQ:IMMXImmix Biopharma Inc
22/06/202315h53GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of DirectorsNASDAQ:IMMXImmix Biopharma Inc
20/06/202315h45GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of DirectorsNASDAQ:IMMXImmix Biopharma Inc
16/06/202315h43GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of DirectorsNASDAQ:IMMXImmix Biopharma Inc
14/06/202313h30GlobeNewswire Inc.Immix Biopharma Completes $5 Million At-The-Market Equity Offering ProgramNASDAQ:IMMXImmix Biopharma Inc
13/06/202323h27Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:IMMXImmix Biopharma Inc
12/06/202315h49GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of DirectorsNASDAQ:IMMXImmix Biopharma Inc
08/06/202312h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IMMXImmix Biopharma Inc
26/05/202315h53GlobeNewswire Inc.Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing SiteNASDAQ:IMMXImmix Biopharma Inc
21/05/202322h05GlobeNewswire Inc.Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical TrialNASDAQ:IMMXImmix Biopharma Inc
21/05/202322h00GlobeNewswire Inc.Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical TrialNASDAQ:IMMXImmix Biopharma Inc
12/05/202323h01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:IMMXImmix Biopharma Inc
04/05/202318h30GlobeNewswire Inc.Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)NASDAQ:IMMXImmix Biopharma Inc
03/05/202314h00GlobeNewswire Inc.Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody TislelizumabNASDAQ:IMMXImmix Biopharma Inc
26/04/202323h30GlobeNewswire Inc.Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in ParisNASDAQ:IMMXImmix Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:IMMX

Dernières Valeurs Consultées

BIT
P19KE4
BNP Paribas Issuance
BIT
P16KA8
BNP Paribas Issuance
BIT
I06589
Banca Imi
BIT
P16JY0
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés